BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Core Viewpoint - BiomX Inc. has disclosed a going concern qualification in its audit opinion for the fiscal year ended December 31, 2024, as required by NYSE regulations [1] Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies aimed at targeting and eliminating harmful bacteria associated with chronic diseases that have significant unmet medical needs [2] - The company utilizes its BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against proprietary bacterial targets [2]